Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 1 of 81 PageID #: 5702
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`Dep. Ex. No.
`Pinchasi 18
`
`Doc Dates
`
`Description
`
`1313
`
`1314
`
`1315
`
`1316
`
`1317
`
`1318
`
`1319
`1320
`1321
`
`1322
`
`1323
`
`1324
`
`1325
`
`1326
`
`1327
`1328
`1329
`
`1330
`
`Klinger 20
`
`Pinchasi 22
`
`Klinger 39
`
`Kreitman 4; Klinger 38
`
`Klinger 40
`
`Volovsky 9
`
`Klinger 41
`
`Pinchasi 21
`
`Pinchasi 20
`
`Pinchasi 28
`
`Kreitman 5; Klinger 21
`
`Wynn 6
`
`Klinger 22
`
`Klinger 5
`
`MARKED AS JTX EXHIBIT
`
`MARKED AS JTX EXHIBIT
`
`Production No.
`(if applicable)
`TEVCOP01592453 -
`TEVCOP01592480
`
`TEVCOP00522876 -
`TEVCOP00522884
`
`
`
`TEVCOP01586443 -
`TEVCOP01586450
`
`TEVCOP00510969 -
`TEVCOP00510971
`
`TEVCOP00510964 -
`TEVCOP00510971
`
`TEVCOP00510807 -
`TEVCOP00510813
`TEVCOP00511175 -
`TEVCOP00511178
`
`TEVCOP00009409 -
`TEVCOP00009054
`TEVCOP00511229 -
`TEVCOP00511231
`TEVCOP00832210 -
`TEVCOP00832225
`TEVCOP00832780 -
`TEVCOP00832821
`
`TEVCOP00689234 -
`TEVCOP00689237
`TEVCOP00510523 -
`TEVCOP00510524
`
`TEVCOP00688099 -
`TEVCOP00688117
`TEVCOP00676705 -
`TEVCOP00676707
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`R, F, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`R, 403, IN, F, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`403, 26, F
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 23
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 2 of 81 PageID #: 5703
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Doc Dates
`
`Description
`
`Dep. Ex. No.
`Kreitman 7
`
`Klinger 36
`
`Kreitman 8
`
`Kreitman 10
`
`Kreitman 11
`
`Klinger 37
`
`Kreitman 12
`
`Kreitman 9
`
`Kreitman 14
`
`Hassler 9
`
`Kreitman 15
`
`Klinger 19
`
`Kreitman 16; Klinger
`31
`
`Kreitman 17
`
`Def. Ex. No.
`
`1331
`
`1332
`
`1333
`
`1334
`
`1335
`
`1336
`
`1337
`
`1338
`
`1339
`
`1340
`
`1341
`
`1342
`
`1343
`
`1344
`
`1345
`
`1346
`
`Production No.
`(if applicable)
`TEVCOP00417425 -
`TEVCOP00417432
`TEVCOP00495191 -
`TEVCOP00495198
`
`TEVCOP00604762 -
`TEVCOP00604822
`TEVCOP00604823 -
`TEVCOP00604826
`
`TEVCOP00417461 -
`TEVCOP00417466
`TEVCOP01578387 -
`TEVCOP01578396
`
`TEVCOP00676397 -
`TEVCOP00676405
`
`TEVCOP00746949 -
`TEVCOP00747005
`
`TEVCOP00675968-
`TEVCOP00675971
`
`TEVCOP00747006 -
`TEVCOP00747060
`
`TEVCOP00606154 -
`TEVCOP00606178
`
`TEVCOP00418343 -
`TEVCOP00418345
`TEVCOP00501497 -
`TEVCOP00501514
`TEVCOP00676740 -
`TEVCOP00676745
`
`TEVCOP00613556 -
`TEVCOP00613558
`TEVCOP00496034-
`TEVCOP00496037
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 24
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 3 of 81 PageID #: 5704
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`Dep. Ex. No.
`
`Doc Dates
`
`Description
`
`1347
`
`1348
`
`1349
`
`1350
`
`1351
`
`1351-A
`
`1352
`
`1353
`
`1354
`
`1355
`
`1356
`
`1357
`
`1358
`
`1359
`1360
`1361
`
`1362
`
`1363
`
`1364
`
`1365
`
`Kreitman 19
`
`Pinchasi 1
`
`Pinchasi 1
`
`Hassler 10
`
`Kreitman 18; Klinger
`32
`
`Kreitman 20; Klinger
`33
`
`Kreitman 21; Klinger
`34
`Sheehy 4
`
`Pinchasi 33
`
`Kreitman 22
`
`Kreitman 23
`
`Klinger 16
`
`7/20/2009
`
`MARKED AS JTX EXHIBIT
`Office Action Summary, dated July 20, 2009 (Appl. No.
`11/651,212)
`
`Production No.
`(if applicable)
`TEVCOP00747337-
`TEVCOP00747382
`TEVCOP00826133-
`TEVCOP00826138
`TEVCOP00608638 -
`TEVCOP00608656
`
`TEVCOP00683250-
`TEVCOP00683260
`
`TEVCOP01592516 -
`TEVCOP01592524
`TEVCOP01592516 -
`TEVCOP01592524
`TEVCOP00747555-
`TEVCOP00747585
`TEVCOP00747553 -
`TEVCOP00747554
`TEVCOP00497420
`
`TEVCOP00729915 -
`TEVCOP00729989
`
`TEVCOP00418389 -
`TEVCOP00418391
`TEVCOP00679773-
`TEVCOP00679774
`TEVCOP00675914 -
`TEVCOP00675916
`TEVCOP00439808-
`TEVCOP00439812
`
`TEVCOP00418455 -
`TEVCOP00418464
`TEVCOP00466838-
`TEVCOP00466845
`TEVCOP00466868 -
`TEVCOP00466878
`TEVCOP00417890 -
`TEVCOP00417894
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, R, F, H, 403, RD
`
`A, F, R, 403, RD, NT, 26
`
`A, F, R, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, 403, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`H, 403, IN
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 25
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 4 of 81 PageID #: 5705
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Doc Dates
`
`Description
`
`Def. Ex. No.
`
`1366
`
`1367
`
`1368
`
`1369
`
`1370
`
`1371
`
`1372
`
`1373
`
`1374
`
`1375
`1376
`1376-A
`
`1377
`
`1378
`
`1379
`
`1380
`
`1381
`
`1382
`
`1383
`
`Dep. Ex. No.
`Klinger 15
`
`Kreitman 24
`
`Kreitman 25
`
`Kreitman 26; Hassler
`11
`Kreitman 27
`
`Kreitman 28
`
`Klinger 14
`
`Kreitman 29
`
`Klinger 17
`Pinchasi 2
`Pinchasi 2
`
`Kreitman 30
`
`Wynn 7
`
`Klinger 18
`
`Klinger 12
`
`Wynn 8
`
`Klinger 13
`
`Kreitman 31
`
`Production No.
`(if applicable)
`TEVCOP00608990 -
`TEVCOP00609001
`
`TEVCOP00418501 -
`TEVCOP00418504
`TEVCOP00609060 -
`TEVCOP00609065
`TEVCOP00609127-
`TEVCOP00609129
`TEVCOP00417936 -
`TEVCOP00417939
`TEVCOP00417940 -
`TEVCOP00417945
`TEVCOP00417953 -
`TEVCOP00417957
`TEVCOP00508159 -
`TEVCOP00508162
`
`TEVCOP00417969 -
`TEVCOP00417973
`
`TEVCOP00417975
`TEVCOP01592526
`TEVCOP01592526
`
`TEVCOP00418628 -
`TEVCOP00418636
`TEVCOP00440958 -
`TEVCOP00440961
`TEVCOP00610436 -
`TEVCOP00610486
`
`TEVCOP00528505 -
`TEVCOP00528535
`
`TEVCOP00611911 -
`TEVCOP00611922
`TEVCOP00844154 -
`TEVCOP00844158
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`A, F, R, 403, RD, NT, 26
`A, F, R, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`TEVCOP00463728
`
`A, R, F, H, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 26
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 5 of 81 PageID #: 5706
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Description
`MARKED AS JTX EXHIBIT
`
`MARKED AS JTX EXHIBIT
`INTENTIONALLY LEFT BLANK
`
`Dep. Ex. No.
`
`Doc Dates
`
`Volovsky 11
`
`Kreitman 33
`
`Sheehy 9
`
`Sheehy 6
`
`Klinger 42
`
`Klinger 42
`
`Sheehy 5
`
`Sheehy 14; Derkacz 4
`
`Sheehy 15
`
`Sheehy 16
`
`Hassler 5
`
`Sheehy 17
`
`Sheehy 26
`
`Def. Ex. No.
`1384
`1385
`
`1386
`
`1387
`
`1388
`
`1389
`
`1389-A
`
`1390
`1391
`1392
`1393
`
`1394
`
`1395
`
`1396
`
`1397
`
`1398
`
`Production No.
`(if applicable)
`
`TEVCOP00179325 -
`TEVCOP00179331
`TEVCOP00596439 -
`TEVCOP00596539
`
`TEVCOP00634257 -
`TEVCOP00634263
`
`TEVCOP00471861 -
`TEVCOP00471863
`TEVCOP01615977 -
`TEVCOP01615986
`TEVCOP01615977 -
`TEVCOP01615986
`
`TEVCOP00658195 -
`TEVCOP00658197
`
`TEVCOP00476101 -
`TEVCOP00476113
`TEVCOP00421351 -
`TEVCOP00421361
`
`TEVCOP00424000 -
`TEVCOP00424038
`
`TEVCOP00630378 -
`TEVCOP00630381
`TEVCOP00660479 -
`TEVCOP00660524
`
`TEVCOP00657786 -
`TEVCOP00657795
`
`Teva's Objections
`
`Admitted
`
`403, R, F
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, 403, RD, NT, 26
`
`A, F, R, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 27
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 6 of 81 PageID #: 5707
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Dep. Ex. No.
`Klinger 6
`
`Klinger 44
`
`Klinger 44
`
`Hassler 6
`
`Sheehy 7
`
`Sheehy 30
`
`Sheehy 20; Derkacz 6
`
`Kolodny 2
`
`Hassler 2; Kolodny 3
`
`Hassler 23
`
`Volovsky 23
`
`Volovsky 20
`
`Volovsky 21
`
`Volovsky 2
`
`Sheehy 8
`
`Sheehy 13
`
`Def. Ex. No.
`
`1399
`
`1400
`
`1400-A
`
`1401
`
`1402
`
`1403
`
`1404
`
`1405
`
`1406
`
`1407
`
`1408
`
`1409
`
`1410
`
`1411
`
`1412
`
`1413
`
`1414
`
`Doc Dates
`
`Description
`
`MARKED AS JTX EXHIBIT
`
`Production No.
`(if applicable)
`TEVCOP00538885 -
`TEVCOP00538918
`
`TEVCOP01615987 -
`TEVCOP01615988
`TEVCOP01615987 -
`TEVCOP01615988
`
`TEVCOP00638063 -
`TEVCOP00638097
`TEVCOP00804150 -
`TEVCOP00804153
`TEVCOP00658799 -
`TEVCOP00658837
`TEVCOP00753992 -
`TEVCOP00754021
`TEVCOP00423514 -
`TEVCOP00423517
`
`TEVCOP00423780 -
`TEVCOP00423785
`
`TEVCOP00768092 -
`TEVCOP00768178
`
`TEVCOP00294689 -
`TEVCOP00294784
`
`TEVCOP00423822 -
`TEVCOP00423823
`TEVCOP00423824 -
`TEVCOP00423827
`TEVCOP00395672 -
`TEVCOP00395679
`
`TEVCOP00631828 -
`TEVCOP00631832
`TEVCOP00423302 -
`TEVCOP00423320
`
`
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, F, R, 403, RD, NT, 26
`
`A, F, R, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`403, R, 26, F
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 28
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 7 of 81 PageID #: 5708
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Doc Dates
`
`Description
`
`MARKED AS JTX EXHIBIT
`
`MARKED AS JTX EXHIBIT
`
`Dep. Ex. No.
`Volovsky 13
`
`Kolodny 5
`
`Kolodny 6
`
`Pinchasi 3
`Pinchasi 3
`
`Hassler 21
`
`Kolodny 31
`
`Kolodny 7
`
`Sheehy 12; Derkacz 5
`
`Volovsky 5
`
`Volovsky 3
`
`Volovsky 7
`
`Volovsky 6
`
`Hassler 3
`
`Kolodny 14; Fox 14
`
`Sheehy 31; Derkacz 9
`
`Def. Ex. No.
`
`1415
`
`1416
`
`1417
`1418
`1418-A
`
`1419
`
`1420
`
`1421
`
`1422
`1423
`
`1424
`
`1425
`
`1426
`1427
`1428
`1429
`
`1430
`
`1431
`
`1432
`1433
`1434
`1435
`
`1436
`
`
`
`Production No.
`(if applicable)
`TEVCOP00312413 -
`TEVCOP00312427
`TEVCOP00478832 -
`TEVCOP00478852
`
`TEVCOP00422192
`
`TEVCOP01592527
`TEVCOP01592527
`
`TEVCOP00631616 -
`TEVCOP00631617
`TEVCOP00633849 -
`TEVCOP00633955
`TEVCOP00434708 -
`TEVCOP00434709
`TEVCOP00897493 -
`TEVCOP00897498
`
`TEVCOP00002931 -
`TEVCOP00002932
`
`TEVCOP00003211 -
`TEVCOP00003216
`TEVCOP00003308 -
`TEVCOP00003333
`TEVCOP00005193
`
`TEVCOP00717911 -
`TEVCOP00717912
`TEVCOP01616003 -
`TEVCOP01616006
`TEVCOP01580074 -
`TEVCOP01580130
`
`TEVCOP01616259
`
`TEVCOP01616228
`TEVCOP01616229
`TEVCOP01616233 -
`TEVCOP01616234
`TEVCOP01616247 -
`TEVCOP01616254
`
`Teva's Objections
`
`Admitted
`
`R, 403, F, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`A, F, R, 403, RD, NT, 26
`A, F, R, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`403, R, 26
`
`A, R, F, H, 403, RD, 26
`
`403, R, F, 26
`403, R, F, 26
`
`A, R, F, H, 403, RD, 26
`
`DUP, IN, 403
`
`A, R, F, H, 403, RD, 26
`
`IN, 403, I
`DUP, IN, 403
`DUP, IN, 403
`DUP, IN, 403
`
`DUP, IN, 403
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 29
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 8 of 81 PageID #: 5709
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`1437
`
`1438
`
`1438-A
`1439
`1440
`
`1441
`
`1442
`1443
`1444
`1445
`1446
`
`1447
`
`1448
`
`1449
`
`1449-A
`
`1450
`
`1451
`
`1452
`
`1453
`
`1454
`
`1455
`
`1456
`
`Dep. Ex. No.
`Sheehy 29; Derkacz 10
`
`Doc Dates
`
`Description
`
`MARKED AS JTX EXHIBIT
`
`MARKED AS JTX EXHIBIT
`
`Klinger 43
`
`Klinger 43
`
`Kolodny 8
`
`Sheehy 19
`
`Fox 13
`
`Sheehy 21
`
`Derkacz 8
`
`Hassler 12
`
`Klinger 45
`
`Klinger 45
`
`Wynn 9
`
`Wolinsky 9
`
`Sheehy 27; Derkacz 7
`
`Sheehy 22; Derkacz 11
`
`Wolinsky 8
`
`Kolodny 9
`
`Kolodny 4
`
`Production No.
`(if applicable)
`TEVCOP00643362 -
`TEVCOP00643513
`TEVCOP01615991 -
`TEVCOP01615992
`TEVCOP01615991 -
`TEVCOP01615992
`
`TEVCOP00428557 -
`TEVCOP00428558
`TEVCOP00908684 -
`TEVCOP00908694
`TEVCOP01616012 -
`TEVCOP01616033
`TEVCOP01616223
`TEVCOP00436077
`
`TEVCOP00779166 -
`TEVCOP00779171
`TEVCOP00786526 -
`TEVCOP00786570
`
`TEVCOP01616179 -
`TEVCOP01616182
`TEVCOP01615989 -
`TEVCOP01615990
`TEVCOP01615989 -
`TEVCOP01615990
`UTHealth0000143 -
`UTHealth0000144
`UTHealth0007817 -
`UTHealth0007818
`TEVCOP00432241 -
`TEVCOP00432277
`TEVCOP00438036 -
`TEVCOP00438079
`
`UTHealth0000168 -
`UTHealth0000175
`TEVCOP00964059 -
`TEVCOP00964060
`TEVCOP00427643 -
`TEVCOP00427653
`
`
`
`,
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, F, R, 403, RD, NT, 26
`
`A, F, R, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`DUP, IN, 403
`DUP, IN, 403
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`DUP, IN, 403
`
`A, F, R, 403, RD, NT, 26
`
`A, F, R, 403, RD, 26
`
`403, R, 26
`
`403, R, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`R
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 30
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 9 of 81 PageID #: 5710
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Dep. Ex. No.
`Sheehy 10; Kolodny 10
`
`Doc Dates
`
`Description
`
`Hassler 25
`
`Hassler 15
`
`Hassler 4
`
`Hassler 13
`
`Pinchasi 4
`Pinchasi 4
`
`Pinchasi 5
`Pinchasi 5
`
`Wynn 28
`
`Wynn 26
`
`Hassler 19
`
`Kolodny 11
`
`Volovsky 4
`
`Sheehy 11
`
`Sheehy 25
`
`Sheehy 32
`
`MARKED AS JTX EXHIBIT
`
`Def. Ex. No.
`
`1457
`
`1458
`
`1459
`
`1460
`
`1461
`
`1462
`1462-A
`1463
`1463-A
`
`1464
`1465
`1466
`
`1467
`
`1468
`
`1469
`
`1470
`
`1471
`
`1472
`
`
`,
`
`Production No.
`(if applicable)
`TEVCOP00436980 -
`TEVCOP00436981
`TEVCOP00428581 -
`TEVCOP00428582
`TEVCOP00717983 -
`TEVCOP00717984
`TEVCOP00426000 -
`TEVCOP00426006
`
`TEVCOP00429455 -
`TEVCOP00429457
`
`TEVCOP01592528
`TEVCOP01592528
`
`TEVCOP01592529
`TEVCOP01592529
`
`SYN-40mgGA_0000070 - SYN-
`40mgGA 0000100
`
`TEVCOP01065102 -
`TEVCOP01065153
`TEVCOP00424830 -
`TEVCOP00424836
`
`TEVCOP00425773 -
`TEVCOP00425774
`TEVCOP00395785 -
`TEVCOP00395820
`TEVCOP00437284 -
`TEVCOP00437285
`
`TEVCOP01584696 -
`TEVCOP01584858
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, F, R, 403, RD, NT, 26
`A, F, R, 403, RD, 26
`A, F, R, 403, RD, NT, 26
`A, F, R, 403, RD, 26
`
`403, R, DUP, IN, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A,R, F, H, 403, 26
`
`A, R, F, H, 403, RD, 26
`
`H, 403, F, A, 26
`
`A, R, F, H, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 31
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 10 of 81 PageID #: 5711
`Defendants’ reserve the right to "1071,3839 1:14_CV_011711i1_1§:'\/Cl§pax9199q11mge ‘otngtfiigntl'ed E21|s§9(82/¥%q§—11E1ggfis%0 0f 81 PagelD #: 5711
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Dep. Ex. No.
`
`Doc Dates
`
`Descn‘ption
`
`Teva's Objections
`
`Admitted
`
`Production No.
`if a . ulicable
`TEVCOP01604508 -
`TEVCOP01604509;
`’I‘EVCOP01604538 —
`TEVCOP01604539
`TEVCOP01604570 -
`TEVCOP01604571
`TEVCOP01605127 —
`TEVCOP01605157
`TEVCOP00427524 -
`TEVCOP00427525
`UTHealth0000093
`TEVCOP01593905 -
`TEVCOP01593913
`TEVCOP01596011 —
`TEVCOP01598124
`TEVCOP01597456 -
`TEVCOP01597471
`TEVCOP01597897 —
`TEVCOP01597908
`TEVCOP01598408 -
`TEVCOP01598548
`TEVCOP01599155 —
`TEVCOP01599319
`TEVCOP01615949 -
`TEVCOP01615959
`
`TEVCOP01580718 -
`TEVCOP01580719
`TEVCOP00439192 —
`TEVCOP00439193
`
`UTHealth0004065 —
`UTHealth00042 50
`TEVCOP00428361 -
`TEVCOP00428362
`
`TEVCOP00641660 —
`TEVCOP00641661
`
`TEVCOP00775696 —
`
`IN, R 403, 26
`
`IN, R 403, 26
`
`IN, R, 403,26
`
`A, R, F, H, 403, RD, 26
`
`403, R 26
`
`DUP, IN, 403, 26
`
`DUP, IN, 403
`
`DUP, IN, 403, 26
`
`DUP, IN, 403, 26
`
`DUP, IN, 403, 26
`
`DUP, IN, 403, 26
`
`IN, R, 403,26
`
`R, 403, F, A, 26
`
`A, F, H, 403, RD, 26
`
`A, F, H, 403, RD, 26
`
`DUP, IN, 403, 26
`
`A, F, H, 403, RD
`
`A, R F, H, 403, RD, DEM,
`26
`
`Kolodny 20
`
`Kolodny 21
`
`Kolodny 23
`
`Hassler 18
`
`15
`Wolins
`Marais 7
`
`Kolodny 17
`
`Kolodny 15; Fox 15
`
`Wynn 24; Fox 17
`
`Wynn 25; Fox 18
`
`Kolodny 26
`
`Hassler 1
`
`Sheehy 23
`
`Sheehy 18; Derkacz 12
`
`Wolinsky 14
`
`Hassler 16
`
`Derkacz 13
`
`Derkacz 14
`
`1474
`
`1475
`
`1476
`
`1477
`
`1478
`
`1479
`
`1480
`
`1481
`
`1482
`
`1483
`
`1484
`
`1485
`1486
`
`1487
`
`1488
`1489
`
`1490
`
`1491
`
`1492
`
`1493
`
`. IARKED AS JTX EMIIBIT
`
`)IARKED AS JTX EXHIBIT
`
`a n
`
`u
`
`-
`
`III||||||||||||||||
`__|H|T|Imm_l
`
`Defendants ’ reserve the right to m odtfi‘, amend, or supplement
`
`Page 32
`
`TEVCOP00775699
`
`A, R, F, H, 403) RD, 26
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 11 of 81 PageID #: 5712
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Doc Dates
`
`Description
`
`INTENTIONALLY LEFT BLANK
`
`MARKED AS JTX EXHIBIT
`
`Def. Ex. No.
`
`1495
`
`1496
`
`1497
`
`1498
`
`1499
`
`1500
`
`1501
`
`1502
`
`1503
`
`1504
`
`1505
`
`1506
`
`1507
`
`1508
`
`1509
`
`1510
`
`Dep. Ex. No.
`Hassler 17
`
`Volovsky 25
`
`Volovsky 24
`
`Hassler 14
`
`Hassler 24
`
`Sheehy 28
`
`Marais 8
`
`Kolodny 24
`
`Hassler 22
`
`Wynn 10
`
`Wynn 11
`
`Wolinsky 17; Wynn 16
`
`Wolinsky 18; Wynn 17
`
`Wolinsky 19; Wynn 18
`
`1511
`1511-A
`
`Pinchasi 6
`Pinchasi 6
`
`Production No.
`(if applicable)
`TEVCOP00777792 -
`TEVCOP00777795
`
`TEVCOP00618901 -
`TEVCOP00619103
`
`TEVCOP00420285 -
`TEVCOP00420290
`
`TEVCOP00640550 -
`TEVCOP00640553
`
`TEVCOP00797896 -
`TEVCOP00797941
`
`TEVCOP01581331 -
`TEVCOP01581708
`TEVCOP01601914 -
`TEVCOP01601917
`TEVCOP01602615
`
`TEVCOP00641620 -
`TEVCOP00641641
`
`UTHealth0007888 -
`UTHealth0007889
`UTHealth0007892
`
`UTHealth0000223
`
`UTHealth0000231 -
`UTHealth0000233
`
`UTHealth0000238 -
`UTHealth0000242
`
`TEVCOP01592525
`TEVCOP01592525
`
`Teva's Objections
`
`Admitted
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD, 26
`
`A, R, F, H, 403, RD
`
`A, R, F, H, 403, RD, 26
`
`DUP, IN, 403, 26
`
`DUP, IN, 403, 26
`
`A, R, F, H, 403, RD, 26
`
`403, F, R, 26
`
`403, F, R, 26
`
`403, R, 26
`
`R, 403, 26, F
`
`R, 403, F
`
`A, F, R, 403, RD, NT, 26
`A, F, R, 403, RD, 26
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 33
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 12 of 81 PageID #: 5713
`Defendants ’ reserve the fight to momgffie 1:14_CV_011711'1_1€§:M§pax9113e0411mgegdngtfiigailE-d Eails§3d(82[1§%./1§1171g(gfi%2 0f 81 Pagel D #: 5713
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`_
`
`_
`
`Production No.
`
`,
`
`.
`
`.
`
`TEVCOP01597530
`
`‘ F ' 403 RD NT 2
`
`0‘
`
`Dep. Ex. No.
`Pinchasi 7
`Pinchasi 7
`
`Wolinsky 20; Wynn 19
`
`TEVCOP01592530
`U'I'Health0000290
`
`A, F, R, 403, RD, 26
`
`IL 403, 26, 1=
`
`U'I'Health0000308 —
`
`TEVCOP01593583
`
`Kolodny 18I!|ill
`
`)—'JII—I'JI
`
`H LIIHa
`
`l517
`
`7
`
`1522
`
`Wolinsky 3
`
`1/18/2016
`
`Curriculum Vitae of Jerry s. Wolinsky, M_D_, dated
`Jan .
`18 2016
`
`IL 403 26
`UTHealth0012126
`’
`Sheelly 24
`I
`I
`TEVCOP01592531 -_
`IC, 26, A, E
`TEVCOP01592533 native
`Sheehy 3
`_-. ——-
`
`2/8/2016
`
`Mike Sheehy LinkedIn (Last Visited February 8, 2016),
`
`. s://www.linkedin_com/inlmike—shee . —63a9443
`
`Wynn 12
`
`2/ 10/2016
`
`Stipulation and [Proposed] Order Concerning Claim
`
`Fox 8; McKeague 5
`
`2/ 12/2016
`
`Stipulation and [Proposed] Order Concerning Claim
`
`Derkacz 2
`
`2/24/2016
`
`S
`
`3/7/2016
`
`b J .. _e
`I 1.194
`”W“°“T"'“S°‘i"“’f’°“"s'w°““"y’M'””““""‘— H _
`Fe-
`.
`15 2016
`7
`Mike Derkacz LinkedIn, Last seen February 24, 2016 at
`httpszllwwwjinkedincom/in/mikederkacz .
`
`H, K 403, 25
`
`Order Construing the Terms of US. Patent Nos.
`8,232,250, 8,399,413, 8,969,302 and 9,155,776, dated
`March 7 7016 I I 714
`
`403
`
`MARKED As JTX EXHIBIT ———
`'I'EVCOP00717340
`
`A, F, H, 403, RD, 26
`
`Kolodny l9
`
`IN, R. 403, 26 _
`TEVCOP01592609
`MARKED As JTX EXHIBIT ———
`TEVCOP01592654 —
`'I'EVCOP01592657
`
`1N, R, 403, 26
`
`— MARKED AS er EXHIBIT ———
`
`Defendants ’ reserve the right to modify, amend, or supplement
`
`Page 34
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 13 of 81 PageID #: 5714
`Defendants’ reserve the right to modlggase 1:14_CV_011711i1_1§:'\/Cl§pax9199qdmge ‘otngtfiiggtl'ed 5!ng(82/k%/}§_11E1g&€15%3 0f 81 PagelD #: 5714
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Dep. Ex. No.
`
`Doc Dates
`
`Descn‘ u tion
`
`Pi‘oduction No.
`11' a . ulicable
`
`Teva's Objections
`
`Admitted
`
`H 'JIOJ 'JI l|. IARKED AS JTX EEG-IIBIT
`
`Kolodny 16
`
`TEVCOP01601875 -
`TEVCOP01601887
`TEVCOP01615976
`
`TEVCOP01615993 -
`TEVCOP01616096
`7 _
`TEVCOP0161601_
`TEVCOP01616033
`
`TEVCOP01616055 —
`TEVCOP01616058
`
`TEVCOP01616090 —
`TEVCOP01616093
`
`TEVCOP01616179 -
`TEVCOP01616455
`
`TEVCOP01616271 —
`TEVCOP01616282
`
`TEVCOP01616480 -
`TEVCOP01616784
`
`TEVCOP01616583 —
`TEVCOP01616596
`
`TEVCOP01616614—
`TEVCOP01616616
`
`TEVCOP01616617 —
`TEVCOP01616618
`.
`7 —
`TEVCOP0161663-
`TEVCOP01616639
`
`TEVCOP01616654 —
`TEVCOP01616663
`
`TEVCOP01616951-
`TEVCOP01617152
`
`TEVCOP01616960 —
`TEVCOP01616973
`
`TEVCOP01617056 —
`TEVCOP01617071
`TEVCOP01617153
`
`TEVCOP01617154 -
`TEVCOP01617330
`7 _
`TEVCOP016172_1
`TEVCOP01617236
`
`TEVCOP01618190 -
`TEVCOP01618502
`
`TEVCOP01618253 —
`TEVCOP01618267
`
`y—a U!.8VII
`
`F, R, IN, 403
`DUP, R, 403
`
`DUP, IN, 403
`
`DUP, IN. 403
`’
`
`DUP, IN, 403
`
`DUP, IN. 403
`’
`
`DUP, IN, 403
`
`DUP, IN. 403
`’
`
`DUP,]1\L403,I
`
`DUP, IN, 403
`
`DUP, 1N, 403,1
`
`DUP, IN, 403
`
`DUP. IN? 403
`
`DUP, IN, 403
`
`DUP, 1N. 403,1
`
`DUP, IN, 403
`
`DUP‘ H‘L 403
`R; 1006
`
`DUP, IN: 403
`
`DUP, IN. 403
`’
`
`DUP, IN: 403
`
`DUP, IN, 403
`
`Defendants ’ reserve the right to m odm', amend, or supplement
`
`Page 35
`
`TEVCOP01618399 —
`TEVCOP01618414
`
`DUP, IN: 403
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 14 of 81 PageID #: 5715
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`1554
`1555
`
`1556
`
`1557
`
`1558
`
`1559
`
`1560
`
`1561
`1562
`1563
`
`1564
`
`1565
`1566
`1567
`
`1568
`
`1569
`
`1570
`
`1571
`
`Doc Dates
`
`Description
`
`MARKED AS JTX EXHIBIT
`
`Production No.
`(if applicable)
`UTHealth0002863
`
`Dep. Ex. No.
`Wolinsky 4
`
`Marais 4
`
`Marais 5
`
`Marais 6
`
`4/19/2016
`
`4/19/2016
`
`Green 2; Au 3
`
`4/19/2016
`
`6/15/2016
`
`6/15/2016
`
`6/15/2016
`
`7/29/2016
`4/19/2016
`
`4/19/2016
`
`4/19/2016
`
`4/19/2016
`
`4/19/2016
`
`Green 19
`
`Hay 2
`
`Expert Report of Ari Green, M.D., dated April 19, 2016
`with Related Exhibits A&B and Exhibits 1-16
`Exhibits attached to the Expert Report of Dr. Ari Green;
`& Documents Considered by Dr. Ari Green – Exhibit B
`to Expert Report of Ari Green, M.D., dated April 19,
`2016
`Expert Report of Ari Green, M.D., dated April 19, 2016
`
`MARKED AS JTX EXHIBIT
`Reply Expert Report of Ari Green, M.D., dated June 15,
`2016 with Exhibit A
`Documents Considered by Dr. Ari Green – Exhibit A to
`Reply Expert Report of Ari Green, M.D., dated June 15,
`2016
`Reply Expert Report of Ari Green, M.D., dated June 15,
`2016
`Supplemental Expert Report of Ari Green, M.D.
`Expert Report of Joel W. Hay, Ph.D., dated April 19,
`2016
`Curriculum Vitae of Joel W. Hay, Ph.D. – Exhibit A to
`Expert Report of Joel W. Hay, Ph.D., dated April 19,
`2016
`Court and Arbitration Cases that Joel W. Hay, Ph.D. has
`offered Reports, Declarations, Depositions or Testimony
`in the Past Four Years – Exhibit B to Expert Report of
`Joel W. Hay, Ph.D., dated April 19, 2016
`
`Expert Report of Joel W. Hay, Ph.D. dated April 19,
`2016 with Exhibits A-C
`Documents Considered by Dr. Joel Hay – Exhibit C to
`Expert Report of Joel W. Hay, Ph.D., dated April 19,
`2016
`
`Teva's Objections
`
`Admitted
`
`F, R, 26
`
`DUP, IN, 403
`
`DUP, IN, 403
`
`DUP, IN, 403
`
`403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`403, H
`
`DUP, 403, H
`
`DUP, 403, H
`DUP, 403, H
`DUP, 403, H
`
`DUP, H, 403
`
`DUP, 403, H
`
`403, H
`
`DUP, 403, H
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 36
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 15 of 81 PageID #: 5716
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`Dep. Ex. No.
`
`Hay 1; Bell 4
`
`1572
`
`1573
`
`1574
`
`1575
`
`1576
`
`1577
`
`1578
`
`1579
`
`1580
`
`1581
`
`1582
`1583
`1584
`1585
`
`1586
`
`1587
`
`1588
`
`1589
`
`Doc Dates
`6/15/2016
`
`6/15/2016
`
`6/15/2016
`
`6/15/2016
`
`6/15/2016
`
`6/15/2016
`
`4/19/2016
`
`4/19/2016
`
`4/19/2016
`
`4/19/2016
`
`Description
`Expert Reply Report of Joel W. Hay, Ph.D., dated June
`15, 2016
`Curriculum Vitae of Joel W. Hay, Ph.D. – Exhibit A to
`Expert Reply Report of Joel W. Hay, Ph.D., dated June
`15, 2016
`Court and Arbitration Cases that Joel W. Hay, Ph.D. has
`offered reports, declarations, depositions or testimony in
`the past four years – Exhibit B to Expert Reply Report of
`Joel W. Hay, Ph.D., dated June 15, 2016
`
`Documents Considered by Dr. Joel Hay – Exhibit C to
`Expert Reply Report of Joel W. Hay, Ph.D., dated June
`15, 2016
`Regression Analysis – Exhibit D to Expert Reply Report
`of Joel W. Hay, Ph.D., dated June 15, 2016
`Reply Expert Report of Joel W. Hay, Ph.D. dated June
`15, 2016 with Exhibits A-D
`Opening Expert Report of Samuel J. Pleasure, M.D.,
`Ph.D., dated April 19, 2016 with Appendix 1-3 &
`Exhibits A-F
`Prosecution Histories of the Patents-in-Suit – Appendix 1
`to Opening Expert Report of Samuel J. Pleasure, M.D.,
`Ph.D., dated April 19, 2016
`Terms Construed as Non-Limiting by the Court –
`Appendix 2 to Opening Expert Report of Samuel J.
`Pleasure, M.D., Ph.D., dated April 19, 2016
`Patents-in-Suit Combined with Markman Edits –
`Appendix 3 to Opening Expert Report of Samuel J.
`Pleasure, M.D., Ph.D., dated April 19, 2016
`Opening Expert Report of Samuel J. Pleasure, M.D.,
`Ph.D., dated April 19, 2016
`MARKED AS JTX EXHIBIT
`MARKED AS JTX EXHIBIT
`Rebuttal Expert Report of Eric Jeffries, M.D., dated May
`27, 2016 with Exhibits A-B and 1-9
`Curriculum Vitae of Eric M. Jeffries, M.D. – Exhibit A to
`Rebuttal Expert Report of Eric Jeffries, M.D., dated May
`27, 2016
`Documents Considered by Dr. Eric Jeffries – Exhibit B to
`Rebuttal Expert Report of Eric Jeffries, M.D., dated May
`27, 2016
`Rebuttal Expert Report of Eric Jeffries, M.D., dated May
`27, 2016
`Expert Report of Ian McKeague, Ph.D., dated May 27,
`2016 with Exhibits A-J
`
`Production No.
`(if applicable)
`
`Teva's Objections
`
`Admitted
`
`DUP, 403, H
`
`DUP, H, 403
`
`DUP, 403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`403, H
`
`403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`DUP, 403, H
`
`H, 403, DEM
`
`Pleasure 1; Fox 19
`
`4/19/2016
`
`5/27/2016
`
`5/27/2016
`
`5/27/2016
`
`5/27/2016
`
`5/27/2016
`
`Jeffries 1
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 37
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 16 of 81 PageID #: 5717
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`Dep. Ex. No.
`
`Doc Dates
`5/27/2016
`
`5/27/2016
`
`5/27/2016
`
`Description
`Expert Report of Ian McKeague, Ph.D., dated May 27,
`2016
`Curriculum Vitae of Ian W. McKeague - Exhibit A to
`Expert Report of Ian McKeague, Ph.D., dated May 27,
`2016
`Documents Considered by Ian McKeague - Exhibit B to
`Expert Report of Ian McKeague, Ph.D., dated May 27,
`2016
`
`1590
`
`1591
`
`1592
`
`1593
`
`1594
`
`1595
`
`1596
`
`1597
`
`1598
`
`1599
`
`1600
`
`1601
`
`1602
`
`1603
`
`McKeague 2
`
`Marais 9
`
`6/15/2016
`
`6/15/2016
`
`7/19/2016
`
`McKeague 4
`
`7/19/2016
`
`Reply Report of Ian McKeague, Ph.D., dated June 15,
`2016
`Reply Report of Ian McKeague, dated June 15, 2016 with
`Ex. A
`Supplemental Expert Report of Ian McKeague, Ph.D.,
`dated July 19, 2016 with Corrected Tables 2a-2c and
`Exhibits A-C
`Supplemental Expert Report of Ian McKeague, Ph.D.,
`dated July 19, 2016
`
`Production No.
`(if applicable)
`
`Teva's Objections
`
`Admitted
`
`H, 403, DUP
`
`403, H
`
`H, 403
`
`H, 403, DEM
`
`H, 403, DEM
`
`H, 403, DEM
`
`H, 403, DEM
`
`H, 403, DEM
`
`H, 403
`
`DUP, H, 403
`
`H, 403
`
`H, 403
`
`H, 403, DEM
`
`H, 403, DEM
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 38
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 17 of 81 PageID #: 5718
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`
`Dep. Ex. No.
`
`Doc Dates
`
`Description
`
`Production No.
`(if applicable)
`
`
`
`Teva's Objections
`
`Admitted
`
`1604
`
`1605
`
`1606
`
`1607
`
`1608
`1609
`1610
`1611
`1612
`1613
`1614
`1615
`1616
`1617
`1618
`1619
`1620
`
`1621
`
`1622
`
`1623
`
`1624
`1625
`1626
`1627
`1628
`1629
`
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`INTENTIONALLY LEFT BLANK
`Mylan Glatiramer Acetate Prescribing Information, dated
`January 2014
`Amneal Glatiramer Acetate Prescribing Information
`Dr. Reddy’s Glatiramer Acetate Prescribing Information
`
`MYLGA00000315 -
`MYLGA00000343
`
`DRLGA000107 - DRLGA000038
`
`Sandoz Glatiramer Acetate Prescribing Information
`
`SDZ(70)0010678 - SDZ(70)0010706
`
`H, 403, DEM
`
`H, 403, DEM
`
`H, 403, DEM
`
`H, 403, DEM
`
`DUP
`DUP
`
`DUP
`
`DUP
`
`H, R, 403, F, 26
`
`H, R, 403, F
`
`H, R, 403, F
`
`H, 403, DEM, DUP
`
`SYN-40mgGA_0000070 - SYN-
`40mgGA 0000100
`MYLGA00076435 -
`MYLGA00076573
`MYLGA00076585 -
`MYLGA00076717
`
`Jeffries 2
`
`Jan-14
`
`Jan-14
`Jan-14
`
`Jan-14
`
`Jan-14
`
`Synthon Glatriamer Acetate Prescribing Information
`
`11/26/2014
`
`3/31/2015
`
`Teva Citizen Petition submitted to the FDA (Docket No.
`FDA-201-P-0933)
`Teva Citizen Petition submitted to the FDA
`
`Ziemssen 15
`
`Nov-15
`
`McKeague 1
`
`5/27/2016
`
`INTENTIONALLY LEFT BLANK
`Rebif Prescribing Information
`MARKED AS JTX EXHIBIT
`MARKED AS JTX EXHIBIT
`Expert Report of Ian McKeague, Ph.D. with Exhibits A-F
`
`Defendants’ reserve the right to modify, amend, or supplement
`
`Page 39
`
`

`

`Case 1:14-cv-01171-GMS Document 259-1 Filed 09/15/16 Page 18 of 81 PageID #: 5719
`In re: Copaxone 40mg Consolidated Cases (C.A. No. 14-1171-GMS)
`Defendants’ reserve the right to modify,
`Defendants' Joint Exhibit List
`amend, or supplement
`
`9/1/2016
`
`Def. Ex. No.
`1630
`1631
`1632
`1633
`1634
`
`1635
`
`1636
`
`1637
`
`1638
`
`1639
`
`1640
`
`1641
`
`1642
`
`1643
`1644
`1645
`
`1646
`
`1647
`1648
`1649
`
`1650
`
`1651
`1652
`1653
`1654
`1655
`
`1656
`
`Dep. Ex. No.
`
`Doc Dates
`
`McKeague 3
`
`10/16/2009
`
`5/26/2015
`
`5/26/2015
`
`6/19/2015
`
`8/25/2015
`
`8/25/2015
`
`9/1/2015
`
`9/9/2015
`
`9/9/2015
`
`9/16/2015
`
`11/20/2015
`
`11/20/2015
`
`11/25/2015
`
`1/22/2016
`
`1/22/2016
`
`1/22/2016
`
`1/26/2016
`2/2/2016
`
`3/16/2016
`
`3/16/2016
`
`Description
`INTENTIONALLY LEFT BLANK
`MARKED AS JTX EXHIBIT
`Definitions of A Person of Ordinary Skill in the Art
`MARKED AS JTX EXHIBIT
`Complaint, Teva Pharms. USA, Inc. v. Mylan Pharms.
`Inc. , No. 09-cv-8824 (S.D.N.Y.)
`Yeda’s Preliminary Patent Owner Response, dated May
`26, 2015 (IPR2015-00643, Paper No. 10)
`Yeda's Preliminary Patent Owner Response (IPR2015-
`00644, Paper No. 12)
`Yeda's Preliminary Patent Owner Response (IPR2015-
`00830, Paper No. 6)
`Decision Institution of Inter Partes Review 37 C.F.R. §
`42.108 (IPR2016-00643, Paper No. 13)
`Decision Institution of Inter Partes Review 37 C.F.R. §
`42.108 (IPR2015-00644, Paper No. 14 )
`Decision Institution of Inter Partes Review 37 C.F.R. §
`42.108 (IPR2015-00830, Paper No. 8)
`Patent Ower's Objections to Evidence (IPR2015-00643,
`Paper No. 15)
`Patent Owner's Objections to Evidence (IPR2015-00644,
`Paper No. 16)
`Patent Owner's Objections to Evidence (IPR2015-00830,
`Paper No. 10)
`INTENTIONALLY LEFT BLANK
`Yeda’s Patent Owner Response (IPR2015-00643, Paper
`No. 26)
`Yeda's Patent Owner Response (IPR2015-00644, Paper
`No. 27)
`Yeda's Patent Owner Response (IPR2015-00830, Paper
`No. 22)
`INTENTIONALLY LEFT BLANK
`Patent Owner's Motion to File Supplemental Information
`(IPR2015-00643, Paper No. 42)
`Patent Owner's Motion to File Supplemental Information
`(IPR2015-00644, Paper No. 43)
`Patent Owner's Motion to File Supplemental Information
`(IPR2015-00830, Paper No. 37)
`Deposition Transcript of Edward J. Fox, MD
`Deposition Transcript of Tjalf Ziemssen
`INTENTIONALLY LEFT BLANK
`Patent Owner's Objections to Evi